PIC1 Injection Therapy for Relapsed/Refractory B-NHL

Clinical Study of PIC1 Injection for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

This is an investigator-initiated trial aimed at assessing the safety and efficacy of PIC1 injection in the treatment of relapsed/refractory B-cell Non-Hodgkin Lymphoma.

Study Overview

• Status: Recruiting
• Conditions: Non-Hodgkin Lymphoma
• Intervention / Treatment: Biological: PIC1 Injection

Detailed Description

This is an open-label, single-arm study to evaluate the efficacy and safety of in vivo generated Chimeric Antigen Receptor T-cell (CAR-T) therapy in patients with relapsed/refractory B-cell Non-Hodgkin Lymphoma. Upon enrollment, subjects will receive an intravenous infusion of PIC1 injection designed for in vivo CAR-T generation. Following infusion, subjects will be hospitalized for observation and evaluated for safety and efficacy. Subjects will be followed for up to 2 years to assess long-term disease control.

• Study Type: Interventional
• Enrollment (Estimated): 18
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Jia Wei; Phone Number: +86 13986102084; Email: jiawei@tjh.tjmu.edu.cn

Study Locations

• China
  • Hubei
    • Wuhan, Hubei, China, 430030
      • Recruiting
      • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
      • Contact: Jia Wei; Phone Number: +86 13986102084; Email: jiawei@tjh.tjmu.edu.cn

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• The patient (or their legally authorized representative) has voluntarily agreed to participate in this clinical trial and has signed the Informed Consent Form (ICF), indicating full understanding of the study's objectives and procedures.
• Aged 18 to 75 years, regardless of gender.

• Histologically or cytologically confirmed B-cell Non-Hodgkin Lymphoma (NHL) according to the WHO 2017 classification, including the following subtypes:

  1. Diffuse Large B-Cell Lymphoma (DLBCL): Including DLBCL, not otherwise specified (DLBCL, NOS); DLBCL associated with chronic inflammation; Primary Cutaneous DLBCL, leg type; and EBV-positive DLBCL, NOS.
  2. High-Grade B-Cell Lymphoma (HGBL): Including HGBL, NOS; and HGBL with MYC and BCL2 and/or BCL6 rearrangements.
  3. Primary Mediastinal Large B-Cell Lymphoma.
  4. T-cell/Histiocyte-rich Large B-Cell Lymphoma.
  5. Transformed DLBCL: DLBCL transformed from prior lymphomas (e.g., Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Marginal Zone Lymphoma).
  6. Follicular Lymphoma Grade 3b (FL3b).
  7. Mantle Cell Lymphoma.

• Patients must have received adequate prior therapy including an anti-CD20 monoclonal antibody and an anthracycline, unless contraindicated or intolerant (i.e., CD20-negative status, intolerance to anti-CD20 mAb, or contraindication to anthracyclines). Patients must meet the definition of Relapsed or Refractory (R/R) disease:

  1. Relapsed: Disease progression or recurrence after achieving a Complete Response (CR) to standard therapy.
  2. Refractory: Best response of Stable Disease (SD) after at least 4 cycles of first-line therapy or at least 2 cycles of last-line therapy (≥2nd line), with SD duration ≤6 months after the last dose; or best response of Progressive Disease (PD) to the last treatment.
  3. No response, disease progression, or relapse after Autologous Stem Cell Transplantation (ASCT).
  4. Patients with transformed lymphoma who received chemotherapy prior to transformation and subsequently failed to achieve response, progressed, or relapsed after salvage therapy post-transformation.
• CD19 positivity confirmed by immunohistochemistry (IHC) or flow cytometry.
• ECOG performance status of 0 or 1.
• Estimated life expectancy of ≥12 weeks.

• At least one measurable lesion per the 2014 Lugano Criteria:

  1. For nodal lesions: Longest diameter >1.5 cm.
  2. For extranodal lesions: Longest diameter >1.0 cm.

• Adequate major organ function defined as:

  1. Cardiac function: Left Ventricular Ejection Fraction (LVEF) ≥40% by echocardiogram.
  2. Renal function: Serum creatinine ≤2.0 × ULN or Creatinine Clearance ≥50 mL/min (calculated by Cockcroft-Gault formula).
  3. Hepatic enzymes: ALT and AST ≤3.0 × ULN (or ≤5.0 × ULN for subjects with hepatic involvement).
  4. Bilirubin: Total bilirubin ≤2.0 × ULN (or ≤3.0 × ULN for subjects with Gilbert's syndrome).
  5. Oxygenation: Oxygen saturation (SpO2) ≥ 92% while breathing room air.
  6. Hematology: Neutrophil Count ≥ 1.0 × 10^9/L; Platelet count ≥ 75 × 10^9/L; Hemoglobin ≥ 80 g/L. (For subjects with bone marrow involvement: Neutrophil ≥ 0.5 × 10^9/L and Platelet count ≥ 50 × 10^9/L.)
• Women of childbearing potential must have a negative pregnancy test. All subjects must agree to use a highly effective method of contraception from the time of signing the ICF until 1 year after the infusion of the investigational product.

Exclusion Criteria:

• Received prior Chimeric Antigen Receptor T-cell (CAR-T) therapy or any other gene-modified cell therapy before screening.

• Received any of the following anti-tumor therapies prior to PIC1 infusion:

  1. medications (e.g., chemotherapy, targeted therapy) within 14 days or 5 half-lives (whichever is longer) before infusion. (excluding lymphodepleting chemotherapy and intrathecal chemotherapy for CNS lymphoma. And intrathecal chemotherapy must be discontinued at least 1 week prior to PIC1 infusion.)
  2. Radiation therapy within 14 days before infusion.

• Has any of the following cardiac conditions:

  1. New York Heart Association (NYHA) Class III or IV congestive heart failure.
  2. Myocardial infarction or coronary artery bypass grafting (CABG) within 6 months prior to enrollment.
  3. Clinically significant ventricular arrhythmias, or a history of unexplained syncope (excluding cases caused by vasovagal reactions or dehydration).
  4. History of severe non-ischemic cardiomyopathy.
• Has an active or uncontrolled infection requiring systemic treatment within 1 week prior to screening.
• Has Grade 2-4 acute GVHD or moderate-to-severe chronic GVHD within 4 weeks prior to screening.
• Has experienced a cerebrovascular accident or seizure within 6 months prior to screening.
• Has experienced a deep vein thrombosis or arterial embolism event within 6 months prior to screening.
• Has a history of other malignancies except for: tumors with no evidence of active disease where treatment was completed >2 years ago; adequately treated carcinoma in situ of the cervix; basal cell or squamous cell skin cancer; radical prostatectomy; radical ductal carcinoma in situ.
• Received a live attenuated vaccine within 4 weeks prior to screening.
• Any other condition that, in the opinion of the Investigator, makes the subject unsuitable for participation in this study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: PIC1 Injection	Biological: PIC1 Injection; Three dose groups (1.0×10^9 TU, 2.0×10^9 TU, 4.0×10^9 TU) were set up, starting from the low dose group climbing to explore the safe and effective dose.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of Adverse Events (AEs) after infusion	Types, frequency and severity of adverse events.	1 month

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall Response Rate (ORR)	The proportion of patients achieving a Complete Response (CR) and Partial Response (PR) post-treatment, as assessed per the Lugano 2014 criteria.	3 months
Best Overall Response (BOR)	The proportion of patients achieving a Complete Response (CR) or Partial Response (PR) post-treatment.	3 months
Duration of Response (DOR)	The time interval from the first documentation of CR or PR to the first documentation of disease progression (PD) or death from any cause, whichever occurs first. This metric applies only to subjects who achieve a confirmed response.	3 months
Progression-Free Survival (PFS)	The time from the initiation of PIC1 treatment to the first occurrence of disease progression or death from any cause, whichever occurs first.	3 months
Overall Survival (OS)	The time from the initiation of PIC1 treatment to death from any cause.	3 months
The maximum concentration (Cmax)	The maximum concentration (Cmax) of CAR-T cells in peripheral blood resulting from in vivo expansion after infusion.	1 month
The time to maximum concentration (Tmax)	The time to reach the maximum concentration (Cmax) of CAR-T cells in peripheral blood resulting from in vivo expansion after infusion.	1 month
AUC 28d	The area under the concentration-time curve of CAR-T cells in peripheral blood over the 28-day period (AUC 28d) after infusion.	1 month
Serum cytokine levels	Serum cytokine levels (such as IL-6, IL-10, TNF-α, IFN-γ) at various time points after infusion.	1 month
Peripheral blood lymphocyte subsets	Peripheral blood lymphocyte subsets (T, B, and NK cell proportions or counts) at various time points after infusion.	3 months

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Viral vector sequences	Viral vector sequences will be detected in blood, saliva, urine, and fecal samples until two consecutive negative results are obtained, to evaluate the potential risk of environmental shedding of the viral vector.	1 month

Collaborators and Investigators

• Sponsor: Chongqing Precision Biotech Co., Ltd

Study record dates

Study Major Dates

• Study Start (Estimated): March 1, 2026
• Primary Completion (Estimated): December 1, 2026
• Study Completion (Estimated): February 1, 2029

Study Registration Dates

• First Submitted: March 2, 2026
• First Submitted That Met QC Criteria: March 4, 2026
• First Posted (Actual): March 6, 2026

Study Record Updates

• Last Update Posted (Actual): March 6, 2026
• Last Update Submitted That Met QC Criteria: March 4, 2026
• Last Verified: March 1, 2026

More Information

Terms related to this study

• Keywords: CAR-T; CD19; in vivo
• Additional Relevant MeSH Terms: Neoplasms; Immune System Diseases; Neoplasms by Histologic Type; Lymphatic Diseases; Lymphoproliferative Disorders; Immunoproliferative Disorders; Lymphoma; Hemic and Lymphatic Diseases; Lymphoma, Non-Hodgkin
• Other Study ID Numbers: PBC108

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No